Skip to main content

Advertisement

SpringerLink
Log in

Adherence to On-Time ART Drug Pick-Up and Its Association with CD4 Changes and Clinical Outcomes Amongst HIV Infected Adults on First-Line Antiretroviral Therapy in Nigerian Hospitals

  • Original Paper
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

Medication adherence is a major determinant of antiretroviral treatment (ART) success. Promptness in medication refill pick-ups may give an indication of medication adherence. This study determined medication refill adherence among HIV positive patients on ART and its association with treatment outcomes in HIV treatment centers in Nigeria. This retrospective multi-center cohort study involved a review of ART refill records for 3534 HIV-positive patients aged 18–60 years who initiated first-line ART between January 2008 and December 2009 and were on therapy for ≥18 months after ART initiation. Drug refill records of these patients for 10 consecutive refill visits after ART initiation were analyzed. The first ten consecutive refill appointment-keeping rates after ART initiation ranged from 64.3 % to 76.1 % which decreased with successive visits. Altogether, 743 (21.1 %) patients were deemed adherent, meaning they picked up their drugs within 7 days of the drug refill appointment date on at least nine out of ten refill visits. The adherent group of patients had a mean CD4 cells increase of 206 ± 6.1 cells/dl after 12 months of ART compared to 186 ± 7.1 cells/dl reported among the nonadherent group (p = 0.0145). The proportion of patients in the adherent category who showed no OIs after 12 months on ART (81 %) was significantly higher when compared to the proportion in the non-adherent category (23.5 %), (p = 0.008). The multivariate analysis showed that the odds of being adherent was 2–3 times more in patients who had a baseline CD4 count of less than 200 cells/dl compared to those with a baseline CD4 of >350 cells/dl. (AOR 2.43, 95 % CI 1.62–3.66). In addition, for patients with baseline CD4 cell count of 201–350 cells/dl, the odds of being adherent was found to be 1.9 compared to those with baseline CD4 of greater than 350 cells/dl (AOR 1.93, 95 % CI 1.27–2.94). Pharmacy refill data can serve as an adherence measure. Adherence to on-time drug pickup on ≥90 % of refill appointments was associated with a better CD4 count response and a reduction in the presence of opportunistic infections in ART patients after 12 months of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. U.S. Department of State. The president’s emergency plan for AIDS relief. Five-year strategy. 2009. Available at: http://www.pepfar.gov/strategy/document/133251.htm Accessed 15 Oct 2011.

  2. World Health Organization (WHO), Joint United Nations Programme on HIV/AIDS, UNICEF (2008). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector. Progress report. pp. 1–77.

  3. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immuno-deficiency virus infection. N Engl J Med. 1998;338:853–60.

    Article  PubMed  Google Scholar 

  4. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43:78–84.

    Article  PubMed  Google Scholar 

  5. Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr. 2007;45:S14–8.

    Article  CAS  PubMed  Google Scholar 

  6. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. J Infect Dis. 2002;185(2):S143–51.

    Article  PubMed  Google Scholar 

  7. Pillay D. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population. Antivir Ther. 2001;6(Suppl 3):15–24.

    PubMed  Google Scholar 

  8. Gill CJ, Hamer DH, Simon JL, Thea DM, Sabin LL. No room for complacency about adherence to antiretroviral therapy in sub-Saharan Africa. AIDS. 2005;19:1243–9.

    Article  PubMed  Google Scholar 

  9. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–97.

    Article  CAS  PubMed  Google Scholar 

  10. Wood E, Montaner JS, Yip B, et al. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antivir Ther. 2004;9:229–35.

    CAS  PubMed  Google Scholar 

  11. Wood E, Hogg RS, Yip B, et al. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:261–8.

    Article  PubMed  Google Scholar 

  12. Low-Beer S, Yip B, O’Shaughnessy MV, et al. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr. 2000;23:360–1.

    Article  CAS  PubMed  Google Scholar 

  13. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158–63.

    Article  CAS  PubMed  Google Scholar 

  14. Wagner JH, Justice AC, Chesney M, et al. VACS 3 project team. patient- and provider-reported adherence: toward a clinically useful approach to measuring antiretroviral adherence. J Clin Epidemiol. 2001;54(Suppl 1):S91–8.

    Article  PubMed  Google Scholar 

  15. Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med. 2000;50:1599–605.

    Article  CAS  PubMed  Google Scholar 

  16. Grossberg R, Gross R. Use of pharmacy refill data as a measure of antiretroviral adherence. Curr HIV/AIDS Rep. 2007;4(4):187–91.

    Article  PubMed  Google Scholar 

  17. Gross R, Zhang Y, Grossberg R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Saf. 2005;14(11):789–93.

    Article  CAS  PubMed  Google Scholar 

  18. World Health Organization (WHO). HIV drug resistance early warning indicators (HIVDR-EWI). 2010.

  19. Hedt BL, Wadonda-Kabondo N, Makombe S, et al. Early warning indicators for HIV drug resistance in Malawi. Antivir Ther. 2008;13:269–75.

    Google Scholar 

  20. Inciardi JF, Leeds AL. Assessing the utility of a community pharmacy refill record as a measure of adherence and viral load response in patients infected with human immunodeficiency virus. Pharmacotherapy. 2005;25(6):790–6.

    Article  PubMed  Google Scholar 

  21. Grossberg R, Zhang Y, Gross R. A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004;57(10):1107–10.

    Article  PubMed  Google Scholar 

  22. Federal Ministry of Health Abuja–Nigeria. National guidelines for HIV/AIDS treatment and care in adolescents and adults. 2007.

  23. Odafe S, Idoko O, Badru T, et al. Patients’ demographic and clinical characteristics and level of care associated with lost to follow-up and mortality in adult patients on first-line ART in Nigerian hospitals. J Int AIDS Soc. 2012;15(2):17424.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Odafe S, Torpey K, Khamofu H, et al. The pattern of attrition from an antiretroviral treatment program in Nigeria. PLoS One. 2012;. doi:10.1371/journal.pone.0051254.

    PubMed  PubMed Central  Google Scholar 

  25. Gardner EM, Burman WJ, Maravi ME, Davidson AJ, et al. Durability of adherence to antiretroviral therapy on initial and subsequent regimens. AIDS Patient Care STDS. 2006;20:628–36.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Townsend ML, Jackson GL, Smith R, et al. Association between pharmacy medication refill-based adherence rates and CD4 count and viral-load responses: A retrospective analysis. Clin Ther. 2007;29(4):711–6.

    Article  PubMed  Google Scholar 

  27. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.

    Article  CAS  PubMed  Google Scholar 

  28. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115–21.

    Article  PubMed  Google Scholar 

  29. El-Khatib Z, Katzenstein D, Marrone G, et al. Adherence to drug-refill Is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011;6(3):e17518. doi:10.1371/journal.pone.0017518.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Sarna A, Pujari S, Sengar AK, Garg R, Gupta I, Van Dam J. Adherence to antiretroviral therapy and its determinants amongst HIV patients in India. Indian J Med Res. 2008;127(1):28–36.

    CAS  PubMed  Google Scholar 

  31. Duwell, M. M., Knowlton, A. R., Nachega, J., et al. Patient-Nominated, Community-Based HIV Treatment Supporters: Patient Perspectives, Feasibility, Challenges, and Factors for Success in HIV-Infected South African Adults. AIDS Patient Care and STDs. 2013; 27(2):96–102. http://doi.org/10.1089/apc.2012.0348.

  32. Tran B, Nguyen L, Nguyen N, et al. Determinants of antiretroviral treatment adherence among HIV/AIDS patients: a multisite study. Global Health Action. 2013. http://dx.doi.org/10.3402/gha.v6i0.19570.

Download references

Acknowledgments

Funding for this paper was provided by FHI 360′s Strengthening Integrated Delivery of HIV/AIDS Services (SIDHAS) project with funds from the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) through U.S. Agency for International Development (USAID) Cooperative Agreement AID-620-A-11-00002. The views expressed in this publication do not necessarily reflect those of FHI 360.

Author information

Authors and Affiliations

  1. FHI 360, Plot 1073 J.S Tarka Street, Area 3 Garki Abuja, Abuja, Nigeria

    Chukwuemeka Anoje, Edward A. Oladele, Titilope Badru, Oluwasanmi Adedokun, Hadiza Khamofu, Olufunso Adebayo & Kwasi Torpey

  2. Howard University Pharmacists and Continuing Education Center, Abuja, Nigeria

    Kenneth Anene Agu & Dorothy Oqua

  3. Department of Family Medicine, Medical University of Southern Africa, Pretoria, South Africa

    Otto Nzapfurundi Chabikuli

  4. FHI 360 South Africa, Hatfield, Pretoria, South Africa

    Otto Nzapfurundi Chabikuli

Authors
  1. Chukwuemeka Anoje
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kenneth Anene Agu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Edward A. Oladele
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Titilope Badru
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oluwasanmi Adedokun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dorothy Oqua
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hadiza Khamofu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Olufunso Adebayo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kwasi Torpey
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Otto Nzapfurundi Chabikuli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chukwuemeka Anoje.

Ethics declarations

Conflict of Interest

The authors; CA, KAE, EAO, TB, OA, DO, HK, OA, KT and ONC declare that they have no conflict of interests.

Research Involved in Human Participants

This article does not contain any studies with human participants performed by any of the authors. FHI 360′s Protection of Human Subjects Committee (PHSC), North Carolina, U.S., and the National Health Research and Ethics Committee (NHREC) Abuja, Nigeria granted an exemption to this study.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Anoje, C., Agu, K.A., Oladele, E.A. et al. Adherence to On-Time ART Drug Pick-Up and Its Association with CD4 Changes and Clinical Outcomes Amongst HIV Infected Adults on First-Line Antiretroviral Therapy in Nigerian Hospitals. AIDS Behav 21, 386–392 (2017). https://doi.org/10.1007/s10461-016-1473-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-016-1473-z

Keywords

Search

Navigation